KKPCF (Kaken Pharmaceutical Co) Cyclically Adjusted Revenue per Share: $15.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KKPCF Kaken Pharmaceutical Co Ltd KKPCF
69 GF Score
Price $26.00
GF Value $25.42
! 2 Warning Signs
View Full Analysis

What is Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Kaken Pharmaceutical Co KKPCF 69 Cyclically Adjusted Revenue per Share is $15.06 as of Mar. 2026. GuruFocus rates KKPCF with a GF Score™ of 69/100 and a GF Value™ of $25.42. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was $3.201. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $15.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kaken Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -2.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kaken Pharmaceutical Co was 2.30% per year. The lowest was 0.60% per year. And the median was 1.20% per year.

As of today (2026-07-21), Kaken Pharmaceutical Co's current stock price is $26.00. Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $15.06. Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.73.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kaken Pharmaceutical Co was 2.99. The lowest was 1.34. And the median was 1.81.


Kaken Pharmaceutical Co  (OTCPK:KKPCF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=26.00/15.06
=1.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kaken Pharmaceutical Co was 2.99. The lowest was 1.34. And the median was 1.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.58 18.65 16.48 14.46 15.06

Kaken Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.46 18.01 18.72 14.26 15.06

KKPCF vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


KKPCF
69GF Score
Kaken Pharmaceutical Co Ltd KKPCF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kaken Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.201/112.7000*112.7000
=3.201

Current CPI (Mar. 2026) = 112.7000.

Kaken Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 6.015 98.100 6.910
201609 6.158 98.000 7.082
201612 5.577 98.400 6.387
201703 4.989 98.100 5.732
201706 5.513 98.500 6.308
201709 5.561 98.800 6.343
201712 5.936 99.400 6.730
201803 5.038 99.200 5.724
201806 5.443 99.200 6.184
201809 5.245 99.900 5.917
201812 5.624 99.700 6.357
201903 4.889 99.700 5.526
201906 5.209 99.800 5.882
201909 5.438 100.100 6.123
201912 5.884 100.500 6.598
202003 4.547 100.300 5.109
202006 4.316 99.900 4.869
202009 4.578 99.900 5.165
202012 5.092 99.300 5.779
202103 4.296 99.900 4.846
202106 4.375 99.500 4.955
202109 4.575 100.100 5.151
202112 4.446 100.100 5.006
202203 4.087 101.100 4.556
202206 3.593 101.800 3.978
202209 3.463 103.100 3.785
202212 3.709 104.100 4.015
202303 3.476 104.400 3.752
202306 3.426 105.200 3.670
202309 3.230 106.200 3.428
202312 3.395 106.800 3.583
202403 3.060 107.200 3.217
202406 3.054 108.200 3.181
202409 6.117 108.900 6.330
202412 4.226 110.700 4.302
202503 3.172 111.100 3.218
202506 3.436 111.700 3.467
202509 3.651 112.000 3.674
202512 3.089 113.000 3.081
202603 3.201 112.700 3.201

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $15.06 mean?
Kaken Pharmaceutical Co (KKPCF) has a Cyclically Adjusted Revenue per Share of $15.06 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Kaken Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $15.06. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share of $15.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $15.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current Cyclically Adjusted Revenue per Share of $15.06. The stock's GF Value™ is $25.42, compared to a current price of $26.00 — trading 2.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $15.06. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current Cyclically Adjusted Revenue per Share is $15.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?

Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued. The current stock price of $26.00 is trading 2.3% above its estimated GF Value™ of $25.42.

Key valuation signals for KKPCF:

  • Cyclically Adjusted Revenue per Share: $15.06
  • GF Value™: $25.42 vs. price of $26.00 (2.3% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kaken Pharmaceutical Co Business Description

Other Exchanges 4521:Japan
Address 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score

Get the complete analysis for KKPCF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.00
Price
$25.42
GF Value